Catheter Ablation of Atrial Fibrillation in Infiltrative Cardiomyopathies: A Narrative Review
- PMID: 39506617
- DOI: 10.1111/jce.16487
Catheter Ablation of Atrial Fibrillation in Infiltrative Cardiomyopathies: A Narrative Review
Abstract
Atrial and ventricular arrhythmias are common in patients with Infiltrative heart diseases. This review discusses ablative techniques for arrhythmias in amyloidosis, sarcoidosis, hemochromatosis, and glycogen storage disorders, primarily focusing on atrial fibrillation (AF). A thorough literature review was conducted on the MEDLINE database to synthesize current knowledge and propose future research directions. AF is the most common arrhythmia identified in patients with amyloidosis due to cellular infiltration and atrial dilation. While catheter ablation is associated with a significantly lower rate of all-cause mortality and admission rate, conflicting data exist regarding the higher risk of pericardial effusion, in-hospital mortality, length of stay, and cost of hospitalization. Cardiac sarcoid predisposes AF due to granulomas, atrial dilation, and scarring. Studies demonstrate encouraging outcomes and low recurrence rates in these patients who undergo ablation for AF, with no difference in complications compared to those without sarcoidosis. AF is the most common arrhythmia in hereditary hemochromatosis (HH), secondary to increased myocardial iron stores and elevated oxidative stress, and is primarily managed by chelation. Scant reports regarding ablation are described for HH and glycogen storage disorders. Catheter ablation is a safe and effective modality for the treatment of AF in infiltrative cardiomyopathy. Future large-scale trials are needed to confirm these findings.
Keywords: ablation; amyloidosis; atrial fibrillation; cryoablation; glycogen storage disorder; hereditary hemochromatosis; infiltrative heart disease; pulse field ablation; sarcoidosis.
© 2024 Wiley Periodicals LLC.
References
-
- E. J. Benjamin, P. Muntner, A. Alonso, et al., “Heart Disease and Stroke Statistics‐2019 Update: A Report From the American Heart Association,” Circulation 139, no. 10 (2019): e56–e528.
-
- S. Colilla, A. Crow, W. Petkun, D. E. Singer, T. Simon, and X. Liu, “Estimates of Current and Future Incidence and Prevalence of Atrial Fibrillation in the U.S. Adult Population,” The American Journal of Cardiology 112, no. 8 (2013): 1142–1147.
-
- A. Goette, J. M. Kalman, L. Aguinaga, et al., “EHRA/HRS/APHRS/Solaece Expert Consensus on Atrial Cardiomyopathies: Definition, Characterization, and Clinical Implication,” Europace 18, no. 10 (2016): 1455–1490.
-
- L. Staerk, J. A. Sherer, D. Ko, E. J. Benjamin, and R. H. Helm, “Atrial Fibrillation,” Circulation Research 120, no. 9 (2017): 1501–1517, https://doi.org/10.1161/CIRCRESAHA.117.309732.
-
- N. L. Pereira, M. Grogan, and G. W. Dec, “Spectrum of Restrictive and Infiltrative Cardiomyopathies,” Journal of the American College of Cardiology 71, no. 10 (2018): 1130–1148, https://doi.org/10.1016/j.jacc.2018.01.016.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
